What is Minomic?
Minomic is an Australian company dedicated to the commercialization of advanced diagnostic tests for solid tumors, with a particular focus on prostate, bladder, and pancreatic cancers. Their flagship product, MiCheck® Prostate, is a blood test available in the US and Australia. This test employs a patented monoclonal antibody and a suite of other biomarkers to generate a clinically relevant risk score for prostate cancer, thereby aiding urologists in their biopsy decision-making processes. The company's strategy is built upon a robust intellectual property portfolio and key strategic alliances to enhance patient outcomes.
How much funding has Minomic raised?
Minomic has raised a total of $3.7M across 1 funding round:
Private Equity
$3.7M
Private Equity (2016): $3.7M, investors not publicly disclosed
What's next for Minomic?
The recent major strategic investment signals a pivotal phase for Minomic, likely aimed at accelerating the commercial rollout of MiCheck® Prostate and expanding its market reach. This capital infusion is expected to fuel further development of their diagnostic pipeline, potentially leading to new tests for other solid tumor types. Minomic's focus on improving diagnostic accuracy and patient stratification positions it for significant growth within the oncology diagnostics sector.
See full Minomic company page
